Floatz logo

OXALIPLATIN

Soft Tissue Sarcoma

OHSU Knight Cancer InstituteSmall moleculePhase 2Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

101 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Brown University
Phase 2BB
N-MET-G-CSF
University of California, Irvine
Phase 3BB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 2BB
DACARBAZINE
Institut Bergonié
Phase 3BB
DOXORUBICIN
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

OXALIPLATIN is also rated in:

exocrine pancreatic carcinomaActive
BBB
Indicative · Phase 2/3
78 / 100
View asset →
colon adenocarcinomaActive
BBB
Indicative · Phase 3
77 / 100
View asset →
rectal cancerActive
BBB
Indicative · Phase 3
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →